Lansing Street Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Lansing Street Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$43.1K	Hold	60	–	–	0.03%	144
2023 Q1	$49.3K	Hold	60	–	–	0.03%	143
2022 Q4	$43.3K	Hold	60	–	–	0.03%	161
2022 Q3	$41K	Hold	60	–	–	0.03%	141
2022 Q2	$35K	Hold	60	–	–	0.03%	142
2022 Q1	$44K	Buy	+60	New	+$38K	0.03%	140

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lansing Street Advisors's REGN Position: Q2 2023 in Review

Lansing Street Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2023 at 60 shares worth $43.1K. The position accounts for 0.03% of the portfolio, ranked #144.

Lansing Street Advisors first reported a position in REGN in Q1 2022 and has held it in 6 quarters since. The position peaked at $49.3K in Q1 2023. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

Lansing Street Advisors held 60 shares of Regeneron Pharmaceuticals worth $43.1K as of Q2 2023.
Lansing Street Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2023.
Regeneron Pharmaceuticals made up 0.03% of Lansing Street Advisors's portfolio in Q2 2023, its #144 holding.
Lansing Street Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
Lansing Street Advisors's Regeneron Pharmaceuticals position peaked at $49.3K in Q1 2023.
1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Lansing Street Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.